Carbohydrate modified ultrafine ceramic nanoparticles for allergen immunotherapy

Pandey, Ravi Shankar; Sahu, Satish; Sudheesh, M.S.; Madan, Jitender; Kumar, Manoj; Dixit, Vinod Kumar

doi:10.1016/j.intimp.2011.02.004

Cited by 46 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sensitized mice were treated by intradermal immunizations with OVA-adsorbed aquasomes compared to alum-adsorbed OVA. Following allergen challenge, lower levels of IgE and of serum histamine were observed as well as weaker symptoms of anaphylaxis 64 . Recently, our group coupled mannan, dextran, and maltodextrin to allergens with the aim to combine hypoallergenicity with specific cell targeting.…”

Section: Nanoparticles In Allergen-specific Immunotherapymentioning

confidence: 99%

Potential of nanoparticles for allergen-specific immunotherapy – use of silica nanoparticles as vaccination platform

Scheiblhofer

Machado

Feinle

et al. 2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Allergen-specific immunotherapy is the only curative approach for the treatment of allergies. There is an urgent need for improved therapies, which increase both, efficacy and patient compliance. Novel routes of immunization and the use of more advanced vaccine platforms have gained heightened interest in this field. Areas covered: The current status of allergen-specific immunotherapy is summarized and novel routes of immunization and their challenges in the clinics are critically discussed. The use of nanoparticles as novel delivery system for allergy vaccines is comprehensively reviewed. Specifically, the advantages of silica nanoparticles as vaccine carriers and adjuvants are summarized. Expert opinion: Future allergen-specific immunotherapy will combine engineered hypoallergenic vaccines with novel routes of administration, such as the skin. Due to their biodegradability, and the easiness to introduce surface modifications, silica nanoparticles are promising candidates for tailor-made vaccines. By covalently linking allergens and polysaccharides to silica nanoparticles, a versatile vaccination platform can be designed to specifically target antigen-presenting cells, render the formulation hypoallergenic, and introduce immunomodulatory functions. Combining potent skin vaccination methods, such as fractional laser ablation, with nanoparticle-based vaccines addresses all the requirements for safe and efficient therapy of allergic diseases.

show abstract

Section: Nanoparticles In Allergen-specific Immunotherapymentioning

confidence: 99%

Potential of nanoparticles for allergen-specific immunotherapy – use of silica nanoparticles as vaccination platform

Scheiblhofer

Machado

Feinle

et al. 2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

show abstract

“…8 Recently, several published papers have reported the characterization of nanoparticles containing allergenic extracts with adjuvant activity 26,27 and ovalbumin. 28,29 These studies showed protection from anaphylactic shock and allergenspecific interleukin-10 production from T cells in animal models suggesting that such formulations may represent sophisticated allergen-delivery systems in allergen specific immunotherapy.…”

Section: Resultsmentioning

confidence: 99%

Lipid nanoparticles as delivery vehicles for the Parietaria judaica major allergen Par j 2

Bondı̀¹,

Montana²,

Craparo³

et al. 2011

IJN

View full text Add to dashboard Cite

Parietaria pollen is one of the major causes of allergic reaction in southern Europe, affecting about 30% of all allergic patients in this area. Specific immunotherapy is the only treatment able to modify the natural outcome of the disease by restoring a normal immunity against allergens. The preparation of allergen-solid lipid nanoparticles as delivery vehicles for therapeutic proteins, P. judaica major allergen Par j 2, was investigated. The Par j 2 allergen was expressed in a large amount in Escherichia coli and purified to homogeneity. Its immunological properties were studied by western blotting and enzyme-linked immunosorbent assay inhibition. Solid lipid nanoparticles were obtained by water-in-oil-in-water multiple emulsion method and characterized in terms of mean size and surface charge. These systems (approximately 250 nm diameter and negative surface charge) incorporated recombinant Par j 2 with 40% or greater efficiency. Moreover, the endotoxin level and anaphylactic activity of the empty solid lipid nanoparticles and recombinant Par j 2-loaded solid lipid nanoparticles were evaluated by looking at the overexpression of CD203c marker on human basophils. These results demonstrate that recombinant Par j 2-nanoparticles could be proposed as safe compositions for the development of new therapeutic dosage forms to cure allergic reactions.

show abstract

“…Enzyme loading in sugar coated nanocore (ECNC/ETNC) 100 mg of sugar coated NC were dispersed in catalase solution 10 mg/ml in 7.4 pH PBS and kept overnight at 4 C. Catalase adsorbed ceramic cores (ECNC/ETNC) were washed three times with de-ionized water by centrifugation at 10 000 rpm for 30 min (REMI C-24, Mumbai, India) and stored at 4 C. The enzyme loaded cores were characterized for morphological characteristics, mean particle size, and size distribution as described before (Loukas et al 1997, Pandey et al 2011.…”

Section: Adsorption Efficiencymentioning

confidence: 99%

Novel catalase loaded nanocores for the treatment of inflammatory bowel diseases

Parihar

Srivastava

Patel

et al. 2016

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is an inflammatory disorder of the digestive tract reported to be primarily caused by oxidative stress. In this study, alginate encapsulated nanoceramic carriers were designed to deliver acid labile antioxidant enzyme catalase orally. Complete system was characterized for size, loading efficiency, in vitro antioxidant assay and in vitro release. The prepared nanoceramic system was found to be spherical with diameter of 925 ± 6.81 nm. The in vitro release data followed the Higuchi model in acidic buffer whereas in alkaline pH sustained and almost first order release of enzyme was observed up to 6 h.

show abstract

Carbohydrate modified ultrafine ceramic nanoparticles for allergen immunotherapy

Cited by 46 publications

References 29 publications

Potential of nanoparticles for allergen-specific immunotherapy – use of silica nanoparticles as vaccination platform

Potential of nanoparticles for allergen-specific immunotherapy – use of silica nanoparticles as vaccination platform

Lipid nanoparticles as delivery vehicles for the Parietaria judaica major allergen Par j 2

Novel catalase loaded nanocores for the treatment of inflammatory bowel diseases

Contact Info

Product

Resources

About